Keyphrases
High-grade Glioma
72%
Radiotherapy
64%
Re-irradiation
55%
Glioblastoma
55%
Geriatrics
53%
Newly Diagnosed Glioblastoma
50%
Older Patients
46%
Phase II Trial
46%
Bevacizumab
44%
Tumor
41%
Radiation Therapy
39%
Recurrent Glioblastoma
38%
Standard of Care
37%
Progression-free Survival
35%
Phase I Trial
35%
Dendritic Cell Vaccine
35%
Overall Survival
35%
Glioblastoma multiforme
34%
Brain Tumor
29%
Chemotherapy
29%
Unfit for Surgery
26%
Meningioma
26%
Median Overall Survival
25%
Primary Brain Tumor
25%
Temozolomide
24%
Checkpoint Inhibitors
20%
Autologous Dendritic Cells
20%
Enzastaurin
17%
DCVax
17%
Bevacizumab Treatment
17%
Author Names
17%
Phase III Clinical Trial
17%
Older Cancer Patients
17%
Magnetic Resonance Imaging
17%
Stereotactic Radiosurgery
14%
Programmed Death-ligand 1 (PD-L1)
13%
Surgical Resection
13%
Enzyme-inducing Antiepileptic Drugs
12%
Median Progression-free Survival
12%
Recurrent Glioma
11%
Cerebrospinal Fluid
11%
Tumor Progression
11%
Head-and-neck Cancer
11%
Randomized Phase II Trial
11%
Re-resection
11%
Central Nervous System Tumors
11%
Newly Diagnosed Patients
10%
Adverse Events
10%
Concurrent Radiotherapy
10%
Concurrent Chemotherapy
10%
Medicine and Dentistry
Glioblastoma
90%
Radiation Therapy
89%
Neoplasm
57%
Ganglioglioma
57%
Geriatrics
53%
Immunotherapy
46%
Re-Irradiation
46%
Overall Survival
38%
Clinical Trial
34%
Bevacizumab
30%
Dendritic Cell Vaccine
27%
Progression Free Survival
27%
Surgery
26%
Malignant Neoplasm
22%
Recurrent Disease
20%
Brain Tumor
20%
Meningioma
17%
Phase I Trials
17%
Temozolomide
15%
Placebo
14%
Dendritic Cell
13%
Intention-to-Treat Analysis
13%
Quality of Life
11%
Tumor Progression
11%
Cisplatin
11%
Disease
10%
Adverse Event
10%
Head and Neck Cancer
10%
Medulloblastoma
10%
Image-Guided Radiation Therapy
10%
Diagnosis
10%
Chemotherapy
10%
Randomized Clinical Trial
9%
Tumor Cell
9%
Ketogenic Diet
8%
Vocimagene Amiretrorepvec
8%
Gliosarcoma
8%
Targeted Therapy
8%
Octreotide
8%
Olradipine
8%
Panobinostat
8%
Skin Carcinoma
8%
Trebananib
8%
COVID-19
8%
Nephrectomy
8%
Stereotactic Body Radiation Therapy
8%
Placebo-Controlled Study
8%
Lung Metastasis
8%
Meningitis
8%
Neck
8%
Pharmacology, Toxicology and Pharmaceutical Science
Glioblastoma
100%
Neoplasm
48%
Glioma
39%
Progression Free Survival
39%
Overall Survival
37%
Bevacizumab
37%
Brain Tumor
32%
Phase I Trials
26%
Chemotherapy
26%
Temozolomide
23%
Anticonvulsive Agent
21%
Phase II Trials
18%
Dendritic Cell Vaccine
18%
Enzastaurin
17%
Adverse Event
15%
Clinical Trial
14%
Placebo
14%
Disease
14%
Methotrexate
13%
Astrocytoma
12%
Malignant Neoplasm
11%
Dexamethasone
11%
Vaccination Policy
11%
Blood-Brain Barrier
11%
Recurrent Disease
11%
Brain Metastasis
10%
Tumor Growth
10%
Prospective Study
10%
Central Nervous System Tumor
9%
Gliosarcoma
8%
Vincristine
8%
Procarbazine
8%
Lomustine
8%
Verubulin
8%
Meningitis
8%
Sialoprotein
8%
Irinotecan
8%
Ipilimumab
8%
Lenalidomide
8%
9 Aminocamptothecin
8%
Panobinostat
8%
Paclitaxel Poliglumex
8%
Melanoma
8%
Glucocorticoid
8%
DNA Methyltransferase
8%
Meningioma
8%
Talampanel
8%
Glutamate Receptor
8%
Trebananib
8%
Placebo-Controlled Study
8%
